Clinical data | |
---|---|
Other names | Progesterone conjugate |
Drug class | Progestogen; Neurosteroid |
Identifiers | |
CAS Number |
VOLT-02 is a water-soluble conjugate of progesterone and a neurosteroid which is under development by Levolta Pharmaceuticals (formerly Voltarra Pharmaceuticals) for the treatment of traumatic brain injury, gynecological disorders, and menstrual disorders.[1] As of March 2017, it is in phase II clinical trials for these indications.[1] The chemical structure of VOLT-02 does not appear to have been released yet.[1]